SCHEMBL10105571

SCHEMBL10105571

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C)c3)c(Cl)c2)ccn1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 13/20 0.66
KDR P35968 6/20 0.66
BRAF P15056 5/20 0.66
RET P07949 4/20 0.66
MAPK14 Q16539 4/20 0.66
EPHX2 P34913 4/20 0.66
ABL1 P00519 3/20 0.66
EPHA2 P29317 3/20 0.66
MAP3K20 Q9NYL2 3/20 0.66
RIPK2 O43353 3/20 0.66
ABCB11 O95342 2/20 0.66
HTR1A P08908 2/20 0.66
PDGFRB P09619 2/20 0.66
ADORA3 P0DMS8 2/20 0.66
KIT P10721 2/20 0.66
FGFR1 P11362 2/20 0.66
PDGFRA P16234 2/20 0.66
FLT1 P17948 2/20 0.66
MAOA P21397 2/20 0.66
EPHA1 P21709 2/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324287 0.92 RAF1 (0.75) RAF1KDRBRAFRETMAPK14
SCHEMBL10105553 0.92 RAF1 (0.79) RAF1KDRBRAFRETMAPK14
SCHEMBL10105567 0.92 RAF1 (0.68) RAF1KDRBRAFRETMAPK14
SCHEMBL6474157 0.89 RAF1 (0.63) RAF1KDRBRAFRETMAPK14
SCHEMBL5086313 0.87 RAF1 (0.87) RAF1KDRBRAFRETMAPK14
SCHEMBL13648348 0.86 RAF1 (0.59) RAF1KDRBRAFRETMAPK14
SCHEMBL14751419 0.85 KDR (0.70) RAF1KDRBRAFRETMAPK14
SCHEMBL14481178 0.85 RAF1 (0.71) RAF1KDRBRAFRETMAPK14
SCHEMBL14550467 0.85 RAF1 (0.66) RAF1KDRBRAFRETMAPK14
SCHEMBL6383620 0.85 RAF1 (0.60) RAF1KDRBRAFRETMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077851-A1 Urea Derivatives as Kinase Inhibitors MEDOLUTION LIMITED (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077851-A1 Urea Derivatives as Kinase Inhibitors MAP3K20, CDK20, MAP3K10 RAF1 15/4885KDR 1768/4885BRAF 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.